Skip to main content
SpringerLink
Log in

Role of autologous stem cell transplantation in multiple myeloma

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achieve a very good response to initial transplantation. Other randomized trials, as well as smaller phase II trials and retrospective studies, have allowed us to improve the process of ASCT in terms of the stem cell collection, conditioning regimens, and extension of the therapy to a wider patient population. The introduction of thalidomide, lenalidomide, and bortezomib have changed the paradigm for treatment of myeloma and significantly improved the outcome for these patients. The role of ASCT will clearly be redefined in the coming years with improvements in other therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983, 2:822–824.

    Article  PubMed  CAS  Google Scholar 

  2. Selby P, Zulian G, Forgeson G, et al.: The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St. Bartholomew’s Hospital studies. Hematol Oncol 1988, 6:173–179.

    Article  PubMed  CAS  Google Scholar 

  3. Barlogie B, Alexanian R, Dicke KA, et al.: High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987, 70:869–872.

    PubMed  CAS  Google Scholar 

  4. Attal M, Harousseau JL, Stoppa AM, et al., for the Intergroupe Français du Myélome: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91–97.

    Article  PubMed  CAS  Google Scholar 

  5. Harousseau JL, Attal M: The role of stem cell transplantation in multiple myeloma. Blood Rev 2002, 16:245–253.

    Article  PubMed  Google Scholar 

  6. Child JA, Morgan GJ, Davies FE, et al.; Medical Research Council Adult Leukaemia Working Party: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875–1883.

    Article  PubMed  CAS  Google Scholar 

  7. Fermand JP, Katsahian S, Divine M, et al.: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Groupe Myelome-Autogreffe. J Clin Oncol 2005, 23:9227–9233.

    Article  PubMed  CAS  Google Scholar 

  8. Barlogie B, Kyle RA, Anderson KC, et al.: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006, 24:929–936.

    Article  PubMed  CAS  Google Scholar 

  9. Blade J, Rosinol L, Sureda A, et al.: High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106:3755–3759.

    Article  PubMed  CAS  Google Scholar 

  10. Palumbo A, Bringhen S, Petrucci MT, et al.: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004, 104:3052–3057.

    Article  PubMed  CAS  Google Scholar 

  11. Fermand JP, Ravaud P, Chevret S, et al.: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92:3131–3136.

    PubMed  CAS  Google Scholar 

  12. Siegel DS, Desikan KR, Mehta J, et al.: Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999, 93:51–54.

    PubMed  CAS  Google Scholar 

  13. Badros A, Barlogie B, Siegel E, et al.: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001, 114:600–607.

    Article  PubMed  CAS  Google Scholar 

  14. Kumar S, Lacy M, Dispenzieri A, et al.: Autologous stem cell transplantation for multiple myeloma in patients over 70 years: a matched comparison with patients under 65 years [abstract]. ASH Annual Meeting Abstracts 2005, 106:1173.

    Google Scholar 

  15. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al.: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000, 1:28–36.

    Article  PubMed  CAS  Google Scholar 

  16. Knudsen LM, Nielsen B, Gimsing P, Geisler C: Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005, 75:27–33.

    Article  PubMed  Google Scholar 

  17. Lee CK, Zangari M, Barlogie B, et al.: Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004, 33:823–828.

    Article  PubMed  CAS  Google Scholar 

  18. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE: Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol 1999, 16:245–254.

    PubMed  CAS  Google Scholar 

  19. Singhal S, Powles R, Sirohi B, et al.: Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002, 30:673–679.

    Article  PubMed  CAS  Google Scholar 

  20. Bensinger WI, Buckner CD, Anasetti C, et al.: Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88:2787–2793.

    PubMed  CAS  Google Scholar 

  21. Harousseau JL, Attal M, Divine M, et al.: Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma [review]. Bone Marrow Transplant 1995, 15:963–969.

    PubMed  CAS  Google Scholar 

  22. Larsson K, Bjorkstrand B, Ljungman P: Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation. Support Care Cancer 1998, 6:378–383.

    Article  PubMed  CAS  Google Scholar 

  23. Kroger N, Zeller W, Hassan HT, et al.: Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998, 76:257–262.

    Article  PubMed  CAS  Google Scholar 

  24. Gazitt Y, Tian E, Barlogie B, et al.: Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996, 87:805–811.

    PubMed  CAS  Google Scholar 

  25. Goldschmidt H, Hegenbart U, Haas R, Hunstein W: Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m 2 ) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996, 17:691–697.

    PubMed  CAS  Google Scholar 

  26. Fitoussi O, Perreau V, Boiron JM, et al.: A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001, 27:837–842.

    Article  PubMed  CAS  Google Scholar 

  27. Corso A, Arcaini L, Caberlon S, et al.: A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002, 87:1041–1045.

    PubMed  CAS  Google Scholar 

  28. Arora M, Burns LJ, Barker JN, et al.: Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004, 10:395–404.

    Article  PubMed  CAS  Google Scholar 

  29. Alegre A, Tomas JF, Martinez-Chamorro C, et al.: Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997, 20:211–217.

    Article  PubMed  CAS  Google Scholar 

  30. Cremer FW, Kiel K, Wallmeier M, et al.: Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol 1998, 26:969–975.

    PubMed  CAS  Google Scholar 

  31. Bruns I, Steidl U, Kronenwett R, et al.: A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006, 46:180–185.

    Article  PubMed  CAS  Google Scholar 

  32. Stewart AK, Vescio R, Schiller G, et al.: Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J. Clin Oncol 2001, 19:3771–3779.

    PubMed  CAS  Google Scholar 

  33. Goldschmidt H, Bouko Y, Bourhis JH, et al.: CD34+ selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: a randomised study from the EBMT [abstract]. Blood 2000, 96:558a.

    Google Scholar 

  34. Moreau P, Facon T, Attal M, et al.: Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002, 99:731–735.

    Article  PubMed  CAS  Google Scholar 

  35. Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55–65.

    PubMed  CAS  Google Scholar 

  36. Attal M, Harousseau JL, Facon T, et al.: InterGroupe Francophone du Myelome: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003, 349:2495–2502.

    Article  PubMed  CAS  Google Scholar 

  37. Cavo M, Cellini C, Zamagni E, et al.: Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma [abstract]. Blood 2004, 104:155a (Abstract 536).

    Google Scholar 

  38. Tricot G, Jagannath S, Vesole DH, et al.: Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995, 16:7–11.

    PubMed  CAS  Google Scholar 

  39. Alvares CL, Davies FE, Horton C, et al.: The role of second autografts in the management of myeloma at first relapse. Haematologica 2006, 91:141–142.

    PubMed  Google Scholar 

  40. Elice F, Raimondi R, Tosetto A, et al.: Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006, 81:426–431.

    Article  PubMed  Google Scholar 

  41. Morris C, Iacobelli S, Brand R, et al.: Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 2004, 22:1674–1681.

    Article  PubMed  CAS  Google Scholar 

  42. Cunningham D, Powles R, Malpas J, et al.: A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998, 102:495–502.

    Article  PubMed  CAS  Google Scholar 

  43. Attal M, Harousseau JL, Leyvraz S, et al.; for the Inter-Groupe Francophone du Myélome (IFM): Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289–3294.

    Article  PubMed  CAS  Google Scholar 

  44. Stewart AK, Chen CI, Howson-Jan K, et al.: Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004, 10:8170–8176.

    Article  PubMed  CAS  Google Scholar 

  45. Sahebi F, Spielberger R, Kogut NM, et al.: Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006, 37:825–829.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, First Street SW, Rochester, MN, 55905, USA

    Shaji Kumar MD

Authors
  1. Shaji Kumar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaji Kumar MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, S. Role of autologous stem cell transplantation in multiple myeloma. Curr Hematol Malig Rep 2, 121–127 (2007). https://doi.org/10.1007/s11899-007-0017-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0017-z

Keywords

Search

Navigation